Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
24 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/10/24/2968565/0/en/iTeos-Therapeutics-to-Highlight-Inupadenant-Preclinical-Translational-and-Phase-2-A2A-005-Clinical-Trial-Data-in-2L-NSCLC-at-ESMO-Immuno-Oncology-Congress.html
07 Oct 2024
// BIOSPACE
https://www.biospace.com/drug-development/tigits-trend-upward-after-iteos-gsk-present-positive-data-at-esmo
https://endpts.com/esmo24-gsk-iteos-rejuvenate-struggling-tigit-space-with-positive-phase-2-jemperli-combo-data-in-lung-cancer/
14 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/14/2946227/0/en/iTeos-Announces-Clinically-Meaningful-Objective-Response-Rate-Observed-at-Every-Dose-in-Follow-up-Interim-Analysis-of-GALAXIES-Lung-201-Study-of-Belrestotug-Dostarlimab-in-First-Li.html
28 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/28/2937389/0/en/iTeos-to-Participate-in-Upcoming-Investor-Conferences.html
20 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/20/2932816/0/en/iTeos-Therapeutics-Announces-Late-Breaking-Oral-Presentation-of-Phase-2-GALAXIES-Lung-201-Interim-Data-at-the-European-Society-for-Medical-Oncology-Congress-2024.html
Details:
EOS-448 (belrestotug, TIGIT antibody) with dostarlimab is being investigated for previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2024
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Not Applicable
Deal Type : Not Applicable
iTeos Reports Positive Objective Response Rate in GALAXIES Lung-201 Study
Details : EOS-448 (belrestotug, TIGIT antibody) with dostarlimab is being investigated for previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Brand Name : EOS-448
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 14, 2024
Details:
The collaboration aims to advance the clinical development of late-stage product EOS-448 (belrestotug) in combination with Dostarlimab for the treatment of PD-L1 high Non-small Cell Lung Cancer.
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: GSK
Deal Size: $2,075.0 million Upfront Cash: $625.0 million
Deal Type: Collaboration July 08, 2024
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : $2,075.0 million
Deal Type : Collaboration
iTeos Doses First Patient in GALAXIES Lung-301 Phase 3, Earns $35M from GSK
Details : The collaboration aims to advance the clinical development of late-stage product EOS-448 (belrestotug) in combination with Dostarlimab for the treatment of PD-L1 high Non-small Cell Lung Cancer.
Brand Name : EOS-448
Molecule Type : Large molecule
Upfront Cash : $625.0 million
July 08, 2024
Details:
Antibody combination, EOS-448 (belrestotug) with dostarlimab is being investigated in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2024
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Not Applicable
Deal Type : Not Applicable
iTeos and GSK Launch Phase 3 Study on Belrestotug and Dostarlimab in Lung Cancer
Details : Antibody combination, EOS-448 (belrestotug) with dostarlimab is being investigated in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Brand Name : EOS-448
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 17, 2024
Details:
The net proceeds from the financing are used to advance the clinical development of EOS-448 (belrestotug) in combination with GSK6097608 and Dostarlimab for non-small cell lung cancer.
Lead Product(s): Belrestotug,GSK6097608,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: RA Capital Management
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 10, 2024
Lead Product(s) : Belrestotug,GSK6097608,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : RA Capital Management
Deal Size : $120.0 million
Deal Type : Public Offering
iTeos Therapeutics Announces $120 Million Registered Direct Offering
Details : The net proceeds from the financing are used to advance the clinical development of EOS-448 (belrestotug) in combination with GSK6097608 and Dostarlimab for non-small cell lung cancer.
Brand Name : EOS-448
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 10, 2024
Details:
EOS-984 is a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ENT1). It is being evaluated for the treatment of triple negative breast cancer.
Lead Product(s): EOS-984
Therapeutic Area: Oncology Brand Name: EOS-984
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Lead Product(s) : EOS-984
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
iTeos Presents EOS-984 Preclinical Data Showing T Cell Activity Restoration
Details : EOS-984 is a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ENT1). It is being evaluated for the treatment of triple negative breast cancer.
Brand Name : EOS-984
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 07, 2024
Details:
In preclinical studies and in blood samples from patients with cancer, treatment with EOS-448 (GSK4428859A) results reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune system effector functions.
Lead Product(s): EOS-448,Dostarlimab
Therapeutic Area: Oncology Brand Name: GSK4428859A
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Lead Product(s) : EOS-448,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : GSK
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In preclinical studies and in blood samples from patients with cancer, treatment with EOS-448 (GSK4428859A) results reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune syst...
Brand Name : GSK4428859A
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 08, 2022
Details:
The addition of EOS-448 results in GSK being the only company with antibodies targeting all three known checkpoints – TIGIT (via EOS-448), CD96 (via GSK’608), and PVRIG (via GSK’562).
Lead Product(s): EOS-448,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IProduct Type: Large molecule
Sponsor: GSK
Deal Size: $2,075.0 million Upfront Cash: $625.0 million
Deal Type: Collaboration June 14, 2021
Lead Product(s) : EOS-448,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : GSK
Deal Size : $2,075.0 million
Deal Type : Collaboration
GSK Pays Up Big for Rights To TIGIT-Targeted Cancer Immunotherapy from Iteos
Details : The addition of EOS-448 results in GSK being the only company with antibodies targeting all three known checkpoints – TIGIT (via EOS-448), CD96 (via GSK’608), and PVRIG (via GSK’562).
Brand Name : EOS-448
Molecule Type : Large molecule
Upfront Cash : $625.0 million
June 14, 2021
Details:
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed.
Lead Product(s): EOS-448
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2021
Details : Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed.
Brand Name : EOS-448
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 10, 2021
Details:
The company's lead candidate EOS-850, a highly selective small molecule antagonist of the adenosine A2a receptor (A2AR), is in an open-label Phase 1/2 clinical trial in adult patients with advanced solid tumors, with initial data expected in the 1H 2021.
Lead Product(s): EOS-850
Therapeutic Area: Oncology Brand Name: EOS-850
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 24, 2020
Lead Product(s) : EOS-850
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $100.0 million
Deal Type : Public Offering
Phase 1/2 oncology biotech iTeos Therapeutics files for a $100 million IPO
Details : The company's lead candidate EOS-850, a highly selective small molecule antagonist of the adenosine A2a receptor (A2AR), is in an open-label Phase 1/2 clinical trial in adult patients with advanced solid tumors, with initial data expected in the 1H 2021.
Brand Name : EOS-850
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 24, 2020
Details:
EOS-448 is being investigated in a Phase 1/2a clinical trial in advanced solid tumors and the dose escalation portion of the trial was initiated in February 2020.
Lead Product(s): EOS-448
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase I/ Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Lead Product(s) : EOS-448
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EOS-448 is being investigated in a Phase 1/2a clinical trial in advanced solid tumors and the dose escalation portion of the trial was initiated in February 2020.
Brand Name : EOS-448
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 22, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?